This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Double-blind Comparative Study of TAK-875

This study has been completed.
Information provided by (Responsible Party):
Takeda Identifier:
First received: September 12, 2011
Last updated: November 7, 2012
Last verified: November 2012
The purpose of this study is to evaluate the efficacy and safety of treatment with TAK-875 in diabetic patients.

Condition Intervention Phase
Diabetes Mellitus Drug: TAK-875 Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Intervention Model: Parallel Assignment

Further study details as provided by Takeda:

Primary Outcome Measures:
  • HbA1c

Enrollment: 192
Study Completion Date: September 2012
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TAK-875 25 mg Drug: TAK-875
Experimental: TAK-875 50 mg Drug: TAK-875
Placebo Comparator: Placebo Drug: Placebo


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  1. The participant is an outpatient.
  2. The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.

Exclusion Criteria:

  1. The participant has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease.
  2. The participant is considered ineligible for the study for any other reason by the investigator or sub-investigator.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01433393

Kisarazu-shi, Chiba, Japan
Matsuyama-shi, Ehime, Japan
Fukuoka-shi Nishi-ku, Fukuoka, Japan
Kasuga-shi, Fukuoka, Japan
Naka-shi, Ibaragi, Japan
Tsuchiura-shi, Ibaragi, Japan
Takamatsu-shi, Kagawa, Japan
Kyoto-shi Fushimi-ku, Kyoto, Japan
Nagasaki-shi, Nagasaki, Japan
Kashihara-shi, Nara, Japan
Kashiwara-shi, Osaka, Japan
Osaka-shi Tsurumi-ku, Osaka, Japan
Sakai-shi Nishi-ku, Osaka, Japan
Shimotsuke-shi, Tochigi, Japan
Chiyoda-ku, Tokyo, Japan
Itabashi-ku, Tokyo, Japan
Ota-ku, Tokyo, Japan
Shinjuku-ku, Tokyo, Japan
Toshima-ku, Tokyo, Japan
Sponsors and Collaborators
  More Information

Responsible Party: Takeda Identifier: NCT01433393     History of Changes
Other Study ID Numbers: TAK-875/CCT-003
U1111-1124-1518 ( Registry Identifier: WHO )
JapicCTI-111604 ( Registry Identifier: JapicCTI )
Study First Received: September 12, 2011
Last Updated: November 7, 2012

Keywords provided by Takeda:
Drug Therapy

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases processed this record on September 21, 2017